Charles Schwab’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-22,638
| Closed | -$34K | – | 3731 |
|
|
2023
Q1 | $34K | Buy |
+22,638
| New | +$34K | ﹤0.01% | 3426 |
|
|
2022
Q3 | – | Sell |
-177,081
| Closed | -$514K | – | 3565 |
|
|
2022
Q2 | $514K | Sell |
177,081
-50,448
| -22% | -$146K | ﹤0.01% | 3069 |
|
|
2022
Q1 | $628K | Sell |
227,529
-7,724
| -3% | -$21.3K | ﹤0.01% | 3033 |
|
|
2021
Q4 | $1.1M | Buy |
235,253
+3,202
| +1% | +$14.9K | ﹤0.01% | 2873 |
|
|
2021
Q3 | $1.98M | Buy |
232,051
+37,480
| +19% | +$319K | ﹤0.01% | 2705 |
|
|
2021
Q2 | $3.19M | Buy |
194,571
+6,555
| +3% | +$108K | ﹤0.01% | 2562 |
|
|
2021
Q1 | $4.15M | Buy |
188,016
+28,429
| +18% | +$628K | ﹤0.01% | 2380 |
|
|
2020
Q4 | $4.94M | Buy |
159,587
+779
| +0.5% | +$24.1K | ﹤0.01% | 2225 |
|
|
2020
Q3 | $3.23M | Buy |
158,808
+61,159
| +63% | +$1.24M | ﹤0.01% | 2299 |
|
|
2020
Q2 | $1.5M | Buy |
97,649
+16,443
| +20% | +$253K | ﹤0.01% | 2515 |
|
|
2020
Q1 | $629K | Buy |
81,206
+1,786
| +2% | +$13.8K | ﹤0.01% | 2635 |
|
|
2019
Q4 | $1.14M | Buy |
79,420
+986
| +1% | +$14.1K | ﹤0.01% | 2556 |
|
|
2019
Q3 | $1.18M | Buy |
78,434
+54,070
| +222% | +$813K | ﹤0.01% | 2522 |
|
|
2019
Q2 | $349K | Buy |
+24,364
| New | +$349K | ﹤0.01% | 2967 |
|